Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), ...

Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced ...

With the FDA approval of its zongertinib in certain non-small cell lung cancer (NSCLC) patients, 175-year-old Boehringer ...

TEM expands its AI-driven Tempus Next platform into breast cancer, targeting key testing gaps to improve care delivery.

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

The Phase 1b program is designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumors whose cancers harbor specific genetic alterations, and in combinat ...

Compugen advances COM701 in ovarian cancer with strong partners, key catalysts ahead, and funding into 2027. Find out why ...

Q2 2025 Earnings Call Transcript August 7, 2025 Puma Biotechnology, Inc. beats earnings expectations. Reported EPS is $0.15, ...

DelveInsight's CLK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Researchers tested more than 65,000 patients with more than 30 solid tumor types and found the rate of HER2 positivity was about 3%.

WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter ...